Jeremy Hoog

8.5k total citations · 1 hit paper
35 papers, 2.7k citations indexed

About

Jeremy Hoog is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jeremy Hoog has authored 35 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Jeremy Hoog's work include Advanced Breast Cancer Therapies (14 papers), Cancer-related Molecular Pathways (12 papers) and Breast Cancer Treatment Studies (10 papers). Jeremy Hoog is often cited by papers focused on Advanced Breast Cancer Therapies (14 papers), Cancer-related Molecular Pathways (12 papers) and Breast Cancer Treatment Studies (10 papers). Jeremy Hoog collaborates with scholars based in United States, Canada and Chile. Jeremy Hoog's co-authors include Matthew J. Ellis, X. Cynthia, Eric P. Winer, Jean J. Zhao, Ian E. Krop, Sandra S. McAllister, Molly J. DeCristo, Thomas M. Roberts, Shom Goel and Shaozhen Xie and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Jeremy Hoog

34 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CDK4/6 inhibition triggers anti-tumour immunity

2017 998 citations Shom Goel, Molly J. DeCristo et al. Nature profile →

Peers

Countries citing papers authored by Jeremy Hoog

Since Specialization

Citations

This map shows the geographic impact of Jeremy Hoog's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeremy Hoog with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeremy Hoog more than expected).

Fields of papers citing papers by Jeremy Hoog

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeremy Hoog. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeremy Hoog. The network helps show where Jeremy Hoog may publish in the future.

Co-authorship network of co-authors of Jeremy Hoog

This figure shows the co-authorship network connecting the top 25 collaborators of Jeremy Hoog. A scholar is included among the top collaborators of Jeremy Hoog based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeremy Hoog. Jeremy Hoog is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models 2024 ·Cancer Research Communications ·Zhanfang Guo, Jingqin Luo, R. Jay Mashl, Jeremy Hoog, (unknown), (unknown), Sherri R. Davies, Rebecca Aft, Jason M. Held, Ramaswamy Govindan, Li Ding, Shunqiang Li, Cornelius von Morze, Gerburg M. Wulf, Kooresh I. Shoghi, X. Cynthia	2
2	Abstract P2-17-03: Preclinical study of trastuzumab deruxtecan (T-Dxd; DS-8201a) in combination with DNA damage response pathway inhibitors in HER2-low/Hormone receptor negative breast cancer patient-derived xenograft models 2023 ·Cancer Research ·(unknown), Zhanfang Guo, Alice Meroni, Emily Cybulla, Jeremy Hoog, Alessandro Vindigni, X. Cynthia	1
3	Cancer-associated exportin-6 upregulation inhibits the transcriptionally repressive and anticancer effects of nuclear profilin-1 2021 ·Cell Reports ·Cuige Zhu, Sun-Joong Kim, Arshag D. Mooradian, (unknown), Ziqian Li, (unknown), Patrick L. Collins, Keren Wang, Zhanfang Guo, Jeremy Hoog, X. Cynthia, Eugene M. Oltz, Jason M. Held, Jieya Shao	14
4	ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106. 2020 ·Journal of Clinical Oncology ·X. Cynthia, Vera J. Suman, A. Marilyn Leitch, Souzan Sanati, Kiran Vij, Gary Unzeitig, Jeremy Hoog, Mark A. Watson, Olwen Hahn, J. Michael Guenther, Abigail S. Caudle, Travis Dockter, Larissa A. Korde, Anna Weiss, Kelly K. Hunt, Clifford A. Hudis, Eric P. Winer, Ann H. Partridge, Lisa A. Carey, Matthew J. Ellis, (unknown)	27
5	Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models 2020 ·UNC Libraries ·Lin Li, Christine E. Ryan, Aleix Prat, Zhanfang Guo, Matthew J. Ellis, (unknown), (unknown), Helen Piwnica‐Worms, Shunqiang Li, Rebecca Aft, Jeremy Hoog, Reece Goiffon, Shirong Cai	12
6	Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers 2018 ·Clinical Cancer Research ·Meenakshi Anurag, (unknown), Jeremy Hoog, Matthew N. Bainbridge, Matthew J. Ellis, Svasti Haricharan	57
7	Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER ⁺ breast cancer 2018 ·The FASEB Journal ·Kevin Shee, (unknown), Frederick S. Varn, (unknown), Nicole A. Traphagen, Philip Owens, X. Cynthia, Jeremy Hoog, Chao Cheng, Todd R. Golub, Ravid Straussman, Todd W. Miller	15
8	Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer 2017 ·Cancer Discovery ·Svasti Haricharan, (unknown), Purba Singh, Kimberly R. Holloway, Meenakshi Anurag, (unknown), (unknown), Jonathan T. Lei, Vera J. Suman, Kelly K. Hunt, John A. Olson, Jeremy Hoog, Shunqiang Li, Shixia Huang, Dean P. Edwards, Shyam M. Kavuri, Matthew N. Bainbridge, X. Cynthia, Matthew J. Ellis	50
9	CDK4/6 inhibition triggers anti-tumour immunity breakdown → 2017 ·Nature ·Shom Goel, Molly J. DeCristo, April C. Watt, (unknown), Jaclyn Sceneay, (unknown), Naveed Khan, Jessalyn M. Ubellacker, Shaozhen Xie, Otto Metzger, Jeremy Hoog, Matthew J. Ellis, X. Cynthia, Susanne Ramm, Ian E. Krop, Eric P. Winer, Thomas M. Roberts, Hye Jung Kim, Sandra S. McAllister, Jean J. Zhao	998
10	Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib 2017 ·Breast Cancer Research ·Nusayba A. Bagegni, Shana Thomas, Ning Liu, Jingqin Luo, Jeremy Hoog, Donald W. Northfelt, Matthew P. Goetz, Andres Forero, Mattias Bergqvist, (unknown), (unknown), Edward M. Suh, Zhanfang Guo, Kiran Vij, Souzan Sanati, Matthew J. Ellis, X. Cynthia	53
11	Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer 2017 ·Breast Cancer Research and Treatment ·Rodrigo Gonçalves, Katherine DeSchryver, X. Cynthia, Tao Yu, Jeremy Hoog, Maggie C.U. Cheang, Erika C. Crouch, Neha Dahiya, Souzan Sanati, Michael Barnes, Luı́s Otávio Sarian, John A. Olson, D. Craig Allred, Matthew J. Ellis	24
12	A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer 2016 ·Clinical Cancer Research ·X. Cynthia, César Sánchez, Feng Gao, Robert J. Crowder, Michael Naughton, Timothy Pluard, (unknown), Zhanfang Guo, Jeremy Hoog, A. Craig Lockhart, Austin Doyle, Charles Erlichman, Matthew J. Ellis	62
13	Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers 2016 ·Nature Communications ·Christopher A. Miller, Yevgeniy Gindin, Charles Lu, Obi L. Griffith, Malachi Griffith, Dong Shen, Jeremy Hoog, Tiandao Li, David E. Larson, Mark A. Watson, Sherri R. Davies, Kelly K. Hunt, Vera J. Suman, Jacqueline Snider, Thomas Walsh, Graham A. Colditz, Katherine DeSchryver, Richard K. Wilson, Elaine R. Mardis, Matthew J. Ellis	51
14	Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer 2016 ·Oncogene ·Jeffrey Hiken, James I. McDonald, Keith F. Decker, César Sánchez, Jeremy Hoog, Nathan D. VanderKraats, Kyle L. Jung, Margaret Akinhanmi, (unknown), Matthew J. Ellis, John R. Edwards	20
15	An mRNA Gene Expression–Based Signature to Identify FGFR1-Amplified Estrogen Receptor–Positive Breast Tumors 2016 ·Journal of Molecular Diagnostics ·Jingqin Luo, Shuzhen Liu, Samuel Leung, Alejandro A. Gru, Tao Yu, Jeremy Hoog, Julie Ho, Sherri R. Davies, D. Craig Allred, Andrea L. Salavaggione, Jacqueline Snider, Elaine R. Mardis, Torsten O. Nielsen, Matthew J. Ellis	11
16	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer 2015 ·Clinical Cancer Research ·X. Cynthia, Jingqin Luo, Michael Naughton, Foluso O. Ademuyiwa, Rama Suresh, Malachi Griffith, Obi L. Griffith, Zachary L. Skidmore, Nicholas C. Spies, Avinash Ramu, Lee Trani, Timothy Pluard, Gayathri Nagaraj, Shana Thomas, Zhanfang Guo, Jeremy Hoog, Jing Han, Elaine R. Mardis, (unknown), Matthew J. Ellis	77
17	Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models 2012 ·Journal of Clinical Investigation ·X. Cynthia, Shirong Cai, Shunqiang Li, Christine E. Ryan, Zhanfang Guo, W. Timothy Schaiff, Lin Li, Jeremy Hoog, Reece Goiffon, Aleix Prat, Rebecca Aft, Matthew J. Ellis, Helen Piwnica‐Worms	166
18	PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast Cancer 2009 ·Cancer Research ·Robert J. Crowder, Chanpheng Phommaly, Tao Yu, Jeremy Hoog, Jingqin Luo, Charles M. Perou, Joel S. Parker, Melinda A. Miller, David G. Huntsman, Lin Li, Jacqueline Snider, Sherri R. Davies, John A. Olson, Mark A. Watson, Anthony J. Saporita, Jason D. Weber, Matthew J. Ellis	174
19	Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer 2009 ·Breast Cancer Research and Treatment ·Matthew J. Ellis, Lin Li, Robert J. Crowder, Tao Yu, Jeremy Hoog, Jacqueline Snider, Sherri R. Davies, Katherine DeSchryver, Dean B. Evans, Jutta Steinseifer, Raj Bandaru, Weihua Liu, Humphrey Gardner, Semiglazov Vf, Mark A. Watson, Kelly K. Hunt, John A. Olson, José Baselga	110
20	Vav1/2/3-null Mice Define an Essential Role for Vav Family Proteins in Lymphocyte Development and Activation but a Differential Requirement in MAPK Signaling in T and B Cells 2003 ·The Journal of Experimental Medicine ·Keiko Fujikawa, Ana V. Miletic, Frederick W. Alt, Roberta Faccio, (unknown), Jeremy Hoog, Jessica Fredericks, Shinzo Nishi, (unknown), Sheri L. Moores, Joan S. Brugge, Fred S. Rosen, Wojciech Swat	195

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact